Industry Growth Overview: The Oral GLP-1 therapy landscape has seen significant advancements in 2025, focusing on improved bioavailability, enhanced efficacy, and patient convenience
Ferroptosis, Cardiac Vulnerability, & Glutathione Dependency Beyond generalized oxidative injury, glutathione critically governs ferroptotic pathways, linking impaired redox control to cardiomyocyte loss and heightened vulnerability to ischemic and metabolic stress
Compounded tirzepatide or compounded GLP-1s: possible alternatives when branded products arent appropriate
In addition, further research is needed to clarify potential sex-specific differences and to better understand the central and peripheral mechanisms of action of GLP-1 and amylin analogues, including whether their effects are additive, synergistic, or potentially divergent in different clinical contexts